Your Article Summary
See Latest ArticlesAVI BioPharma Under Contract with U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu
AVI BioPharma, 06/23/09
AVI BioPharma, Inc. , a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
BayNews International, 12/04/09
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
Sanofi-aventis, 12/04/09
Watson Receives FTC Clearance for Arrow Acquisition
Watson Pharmaceuticals, 12/03/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Amgen, 12/04/09
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09